{"id":99,"date":"2023-09-21T10:00:00","date_gmt":"2023-09-21T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=99"},"modified":"2025-09-01T01:11:18","modified_gmt":"2025-09-01T01:11:18","slug":"china-bd-deal-2023-hansoh-and-gsk-enters-a-1-71-billion-usd-license-on-b7-h4-adc-hs-20089","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2023\/99.html","title":{"rendered":"[China BD Deal 2023] Hansoh and GSK enters a 1.57 billion USD license on B7-H4 ADC HS-20089"},"content":{"rendered":"\n<p>Announced Date: 2023-10-20 (October 20, 2023)<\/p>\n\n\n\n<p>Asset Name: HS-20089<\/p>\n\n\n\n<p>Licensor: Hansoh Pharma&nbsp; (Hansoh) (China)<\/p>\n\n\n\n<p>Licensee (Buyer): GSK plc&nbsp;\uff08UK\uff09<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: Antibody-drug conjugate (ADC)&nbsp;<\/p>\n\n\n\n<p>Asset Target: B7-H4\u00a0\uff0ctopoisomerase inhibitor (TOPOi)\u00a0 payload<\/p>\n\n\n\n<p>Potential indication\uff1agynaecologic cancer, \u00a0ovarian and endometrial cancer\u00a0, other solid tumours<\/p>\n\n\n\n<p>Current Stage: phase I trials in China<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>GSK will obtain exclusive worldwide rights (excluding China\u2019s mainland, Hong Kong, Macau, and Taiwan) to progress clinical development and commercialisation of HS-20089.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Deal Detail:<\/p>\n\n\n\n<p>Upfront payment of\u00a0 $0.85 million;<\/p>\n\n\n\n<p>Milestone payments up to $1.475 billion;<\/p>\n\n\n\n<p>Total up to $1.57 billion.<\/p>\n\n\n\n<p>Additional royalties based on net sales in the licensed territories.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p>GSK enters exclusive license agreement with Hansoh for HS-20089<\/p>\n\n\n\n<p><a href=\"https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-enters-exclusive-license-agreement-with-hansoh-for-hs-20089\/\">https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-enters-exclusive-license-agreement-with-hansoh-for-hs-20089\/<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2023-10-20 (October 20, 2023) Asset Name: HS-20089 Licensor: Hansoh Pharma&nbsp; (Hansoh) (China) Licensee (Buyer): &hellip; <a title=\"[China BD Deal 2023] Hansoh and GSK enters a 1.57 billion USD license on B7-H4 ADC HS-20089\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2023\/99.html\"><span class=\"screen-reader-text\">[China BD Deal 2023] Hansoh and GSK enters a 1.57 billion USD license on B7-H4 ADC HS-20089<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-99","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/99","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=99"}],"version-history":[{"count":2,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/99\/revisions"}],"predecessor-version":[{"id":101,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/99\/revisions\/101"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=99"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=99"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=99"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}